8 July 2014
Commercial Sales of Proprietary 2RT™ Laser post CE Mark
Adelaide, Australia, 8 July 2014 – Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that during June it secured strategically important sales contracts for its 2RT™ retinal therapy in Europe. The devices have been installed and commissioned and the first patients have now been treated.
These contracts represent the first commercial 2RT™ sales made by Ellex since granting of a CE Mark (Conformité Européenne) for 2RT™ in February 2014 for the treatment of early stage Aged-Related Macular Degeneration (early AMD), representing a significant milestone in the Company’s commercialisation program for 2RT™.
The sales were made into Germany and Austria and follow the recent establishment of the Company’s regional headquarters in Berlin.
“Since securing the CE Mark earlier this year we have commenced a limited commercial roll out of 2RT™ to early adopters and key opinion leaders in Europe. We are particularly pleased that leading doctors in the largest ophthalmic market in Europe, have been quick to adopt the technology,” said CEO, Mr. Tom Spurling.
One of the doctors, Hakan Kaymak, MD, senior surgeon in the field of macular, retinal and vitreous surgery at Breyer & Kaymak Augenchirurgie, Düsseldorf, plans to present his clinical experiences with 2RT™ at the German National Ophthalmology Conference in Leipzig during September 2014. Together with Dr Detlev Breyer, Dr. Kaymak is a leading authority in the retinal arena and co-hosts the International Innovative Ophthalmo-Surgery (I.I.O.) research facility.
Mr. Spurling continued: “We aim to work with Dr. Kaymak and other early adopters throughout Europe to advance our knowledge of the benefits of this breakthrough therapy.”
ABOUT BREYER & KAYMAK EYE SURGERY
Breyer & Kaymak Augenchirurgie (Eye Surgery) is renowned for applying state-of-the-art diagnostic procedures and treatments. Each of their eye surgeons performs approx. 2,500 operations per year, and is considered to be a pioneer of their special fields. The chief surgeons, Dr. Detlev Breyer and Dr. Hakan Kaymak, and their team of ophthalmologists offer all services of ophthalmology in accordance with the latest international scientific knowledge.
Age-Related Macular Degeneration (AMD) affects one in seven Australians over the age of 50 (Source: report prepared for Macular Disease Foundation, Access Economics). The economic impact and cost of AMD is high, and is estimated to directly cost the Australian community more than AU$2.6 billion annually (Source: CERA). Current treatment options for AMD only address advanced or end-stage complications associated with the disease. In contrast, 2RT™ offers the potential to apply treatment earlier in the disease process, with the aim of slowing or reversing the process of degeneration, and hence delaying, or preventing, late stage disease.
Retinal Rejuvenation Therapy (2RT™) delivers nanosecond pulses of laser energy to stimulate a natural, biological healing response in the eye to stimulate a process of cellular rejuvenation to preserve and/or improve functional vision, reducing disease progression. These nanosecond pulses generate a response by retinal pigment epithelium (RPE) melanosomes, without causing heat to escape beyond the RPE cell walls. These pulses cause damage to the internal cell structure only: they do not break the cell’s outer membrane. This process of regeneration rejuvenates the entire transport mechanism of the retina, improving visual function and reducing disease progression. This breakthrough approach retains the therapeutic effect of laser therapy whilst eliminating the thermal tissue damage inherent in conventional retinal photocoagulation laser treatment.
Ellex Medical Lasers Limited (ASX:ELX) is a pioneer in the development of medical technologies for the diagnosis and treatment of eye disease. With more than 20,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, France, Germany and Australia, and a network of distribution partners in more than 100 countries. In recent years, Ellex has diversified its product range beyond lasers and ultrasound equipment to include distribution of a number of complementary third-party ophthalmic products. Recently Ellex acquired the canaloplasty micro catheter glaucoma treatment, a recurring revenue stream, which Ellex manufactures at a plant in Menlo Park, California.
For additional information about Ellex and its products, please visit www.ellex.com.
For further information on Ellex, please contact: